The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...
Dupixent has gained positive opinions from KOLs due to the positive data presented from the asset’s two Phase III clinical ...
Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain ...
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the National Medical Products Administration in China has ...
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved ...
The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating ...
Regeneron REGN1.83%increase; green up pointing triangle Pharmaceuticals and Sanofi SAN 0.74%increase; green up pointing triangle have won U.S. Food and Drug Administration expanded approval of their ...
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) Friday said the National Medical Products Administration (NMPA) in China has ...
Regeneron stock XX on XX after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.